Nurix Therapeutics GAAP EPS of -$0.81 misses by $0.08, revenue of $9.04M misses by $6.25M
Seeking Alpha ·
Nurix Therapeutics press release ( NRIX ): Q2 GAAP EPS of -$0.81 misses by $0.08 . Revenue of $9.04M (-79.5% Y/Y) misses by $6.25M . Cash, cash equivalents and marketable securities were $443.5 million as of May 31, 2026, compared to $592.9 million as of November 30, 2025.
DYAX Investor Sentiment
Bullish (Long) 55% · Bearish (Short) 45%
538 participants
Related News
- Ryder raises quarterly dividend by 11% to $1.01/share
- Amazon going after FedEx and UPS customers—Supply Chain Services
- FuboTV appoints former Disney streaming executive Alisa Bowen as CEO
- Fermi falls after launching $350M convertible notes offering
- Trinity Capital reaches $709M in new commitments, $619M in funded investments in Q2
- Can AI automation provide a survival tool amid managed care's thin margins?